Science & Enterprise subscription

Follow us on Twitter

  • New contributed post on Science and Enterprise: https://t.co/XjQZgoAp3S Hands Off! Robots in Modern Medicine
    about 43 mins ago
  • Science funding is a mess. Could grant lotteries make it better? https://t.co/9akEDdSoVb via @voxdotcom
    about 14 hours ago
  • Researchers using a hand-held genomic sequencing device were able to identify targets for combating drug-resistant… https://t.co/5nE7VBwbBE
    about 19 hours ago
  • New post on Science and Enterprise: Portable Sequencer Identifies Drug-Resistant Bacteria https://t.co/6El4ePzZkx #Science #Business
    about 19 hours ago
  • Thank you @innerarchitect for all you do for lung health. Enjoy your weekend. https://t.co/nQRcgaZ2jH
    about 23 hours ago

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

FDA Clears Inhaled Parkinson’s Drug

Brain circuits

A drug administered as an inhaled powder to supplement a common treatment for Parkinson’s disease received approval for marketing from the Food and Drug Administration. . . . → Read More: FDA Clears Inhaled Parkinson’s Drug

Validation Scheme Proposed for Medical Algorithms

Biocircuits illustration

A law school professor urges developers, users, and regulators of machine learning in medicine to validate the algorithms that represent their underlying decision-making processes. . . . → Read More: Validation Scheme Proposed for Medical Algorithms

Lilly, Biopharm Partner on Alzheimer’s Treatment in $2B Deal

Neurons illustration

Eli Lilly and Co. is licensing a a treatment candidate for Alzheimer’s disease from biopharmaceutical company AC Immune that aims to block accumulation of tau proteins in the brain. . . . → Read More: Lilly, Biopharm Partner on Alzheimer’s Treatment in $2B Deal

FDA Clears Mobile App for Opioid Use Disorder

Man with smartphone

The Food and Drug Administration authorized a mobile app, when prescribed by clinicians for patients with opioid use disorder in outpatient treatment programs. . . . → Read More: FDA Clears Mobile App for Opioid Use Disorder

Report – 289 Cell and Gene Therapies in Development

Human T-cell

A report by a pharmaceutical industry organization says nearly 300 new therapies that transfer live cells or genes as treatments for disease are in clinical trials or being reviewed by Food and Drug Administration. . . . → Read More: Report – 289 Cell and Gene Therapies in Development

Trial Results Show Gene Transfers Reverse Sickle Cell Disease

Gene therapy lab

Results from the first 2 participants in a clinical trial show transferring healthy genes to patients with sickle cell disease reverses symptoms of the disease that continues for up to 1 year. . . . → Read More: Trial Results Show Gene Transfers Reverse Sickle Cell Disease

Janssen Licensing Cancer Antibodies in $1.8B Deal

Llama

An affiliate of drug maker Janssen Pharmaceutical is licensing a synthetic antibody to treat blood-related cancers from a developer of antibodies based on the immune system of llamas. . . . → Read More: Janssen Licensing Cancer Antibodies in $1.8B Deal

Trials OK’d for Inherited Eye Disease Therapy with Crispr

Crispr-Cas9 illustration

The company developing a treatment for a rare inherited eye disease using the genome editing technique Crispr received authorization from the Food and Drug Administration to begin clinical trials. . . . → Read More: Trials OK’d for Inherited Eye Disease Therapy with Crispr

Project to Catalog Precision Lung Cancer Immunotherapies

Lung cancer development

A new research initiative in the U.K. is collecting and mapping precise combinations of therapies that invoke the immune system to treat lung cancer. . . . → Read More: Project to Catalog Precision Lung Cancer Immunotherapies

Company Formed to Advance Sickle Cell Gene Therapy

Sickle cell illustration

A Swiss medical technologies company and Cincinnati Children’s hospital in Ohio are starting a new enterprise to commercialize research on gene therapies for inherited blood disorders. . . . → Read More: Company Formed to Advance Sickle Cell Gene Therapy